Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced the publication in this month’s issue of Cancer Immunology Research of an in-depth review describing the rationale for …
Roth Capital’s healthcare analyst Joseph Pantginis weighed in with a few insights on Synta Pharmaceuticals Corp. (NASDAQ:SNTA), after the company announced the enrollment of the …
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90.
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Synta Pharmaceuticals (NASDAQ:SNTA) with a $27 price target, as the company announced interim data from …
In a research report released Thursday, Roth Capital analyst Joseph Pantginis reaffirmed a Buy rating on Synta Pharmaceuticals (NASDAQ:SNTA) with a price target …
In a research note published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Synta Pharmaceuticals (SNTA) with a $27 price …
